Brief: Akari Therapeutics Narrows Pipeline Focus

Akari Therapeutics

01/08/2022 14:46

Aug 1 (Reuters) - Akari Therapeutics PLC  AKTX.O :
    * AKARI THERAPEUTICS NARROWS PIPELINE FOCUS
    * AKARI THERAPEUTICS PLC - PRIORITIZING TWO PIPELINE
PROGRAMS
    * AKARI THERAPEUTICS - CASH, RESOURCES TO BE REALLOCATED TO
PHASE
3 TRIAL OF NOMACOPAN IN SEVERE PEDIATRIC HSCT-TMA, WITH PART A
DATA EXPECTED IN H1 2023
    * AKARI THERAPEUTICS PLC - DISCONTINUING CLINICAL PROGRAM
EVALUATING NOMACOPAN IN BULLOUS PEMPHIGOID (BP)
    * AKARI THERAPEUTICS PLC - COMPANY IS NOT RESTRUCTURING OR
REDUCING HEADCOUNT
    * AKARI THERAPEUTICS - DECISION TO NARROW PIPELINE FOCUS
BASED ON
REASSESSMENT OF DEVELOPMENT TIMELINES, ASSOCIATED COSTS TO
MAXIMIZE VALUE IN PIPELINE
    * AKARI THERAPEUTICS - CASH, RESOURCES TO BE REALLOCATED TO
PRE-CLINICAL PROGRAM OF PAS-NOMACOPAN IN GA

Source text for Eikon:  ID:nGNX7B9xJz 
Further company coverage:  AKTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))